Tempus AI Acquires Personalis for $1.5B in Cancer Diagnostics Deal

Tempus AI Acquires Personalis for $1.5B in Cancer Diagnostics Deal

Tempus AI announced Monday it will acquire Personalis for $1.5 billion, bringing the cancer diagnostics company's blood-based testing technology under the AI-driven precision medicine platform's umbrella. Despite the deal's strategic rationale, shares of both companies declined sharply on the news.

The acquisition follows reports last week that multiple suitors, including Merck, had expressed interest in Personalis. Tempus already held a 12.5% stake in the company prior to the announcement.

Personalis manufactures NeXT Personal, a blood test that screens for circulating tumor DNA—a biomarker indicating cancer recurrence. The technology addresses the minimal residual disease (MRD) market, which analysts estimate could reach $20 billion in addressable opportunity.

Deal Structure and Market Reaction

Tempus is offering $16.25 per share for Personalis, representing a 6% premium to Friday's closing price and a 28% premium to the 30-day average. The transaction values the company at 15.5 times its projected 2027 enterprise value-to-sales ratio, significantly above the typical 3.9x multiple for small- and midcap growth companies in the sector.

Despite the premium, Personalis stock fell 13.3% to close at $13.34, while Tempus AI shares dropped 7.7% to $48.41. The negative market response suggests investor concerns about integration challenges or valuation.

Needham analyst Mike Matson noted that while Tempus has limited current exposure to the MRD market, the company represents "the most logical acquirer" and is paying "a fair price" given Personalis's growth trajectory and recent Medicare reimbursement wins.

Why it matters

The consolidation reflects intensifying competition in cancer diagnostics as AI-powered platforms seek to expand their testing portfolios. Combining Tempus's data infrastructure with Personalis's specialized MRD testing could accelerate development of multi-cancer early detection tools—a category attracting billions in investment as healthcare systems prioritize preventive oncology. The deal also signals that standalone diagnostics companies face pressure to either scale rapidly or join larger platforms with distribution advantages.

Strong Revenue Performance

Alongside the acquisition announcement, Personalis disclosed preliminary second-quarter revenue guidance of $22.4 million, substantially exceeding analyst expectations of $16.8 million. The company also reported 33% sequential growth in test volume, demonstrating commercial traction for its cancer monitoring platform.

Personalis CEO Chris Hall said in a statement that joining Tempus would provide "the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners."

The companies expect the transaction to close in late 2026 or early 2027, pending regulatory approval and the absence of competing bids. Matson noted that antitrust concerns appear limited given Tempus's minimal overlap in the MRD testing space.

Details of the acquisition were first reported by Investor's Business Daily.